Detail of the clinical trial

Title of the trial A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
EudraCT number 2016-002461-66
Protocol number CABL001A2301
Sponsor Novartis Pharma AG, Lichtstrasse 35, Basel 4056, Switzerland
Indications Hemato-oncology
Diagnosis Chronic Myelogenous Leukemia in chronic phase (CML-CP)
Population in clinical trial Adults (18-65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2017
Date of approval by Institute (SÚKL) 5.9.2017
Date of approval by EC 21.9.2017
Date of initiation CT in ČR 26.2.2018
Date of ending CT in ČR
Notice
Sites Ústav hematologie a krevní transfuse,,U Nemocnice 1,Praha 2,128 20
Fakultni nemocnice Hradec Kralova,2. Interni klinika ? oddeleni klinicke hematologie,Sokolska 581,Hradec Kralove,500 05
Fakultni nemocnice Brno,Interni hematologicka a onkologicka klinika,Jihlavska 20,Brno,625 00
Fakultni nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava,708 52

‹‹ Back to list